Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus

Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice

(2012) E Reisoli et al.   CANCER GENE THERAPY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma

(2012) Eleonora Gambini et al.   MOLECULAR THERAPY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor

(2012) Patrizia Nanni et al.   PLoS One

Activity and resistance of trastuzumab according to different clinical settings

(2011) Elda Tagliabue et al.   CANCER TREATMENT REVIEWS

Oncolytic herpes virus retargeted to HER-2

(2011) Pier-Luigi Lollini et al.   CELL CYCLE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rethinking herpes simplex virus: the way to oncolytic agents

(2011) Gabriella Campadelli-Fiume et al.   REVIEWS IN MEDICAL VIROLOGY

Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells

(2009) M. Narayan et al.   CANCER RESEARCH

High metastatic efficiency of human sarcoma cells in Rag2/γc double knockout mice provides a powerful test system for antimetastatic targeted therapy

(2009) Patrizia Nanni et al.   EUROPEAN JOURNAL OF CANCER

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

(2009) Dana Gancz et al.   MOLECULAR IMMUNOLOGY

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

(2009) L. Menotti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice

(2008) Y Kulu et al.   CANCER GENE THERAPY

Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2

(2008) L. Menotti et al.   JOURNAL OF VIROLOGY

A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer

(2008) Yuman Fong et al.   MOLECULAR THERAPY

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

(2008) Roberto Cattaneo et al.   NATURE REVIEWS MICROBIOLOGY